← All Indices
// Index Comparison

ACCE AI Infrastructure vs ACCE Biotech Catalysts

Head-to-head: performance, risk profile, and constituent overlap between two ACCE indices.

US
ACCE AI Infrastructure

Companies building the AI compute, data, and software layer that powers artificial intelligence. This index captures firms across the AI infrastructure stack: semiconductor companies designing GPUs and AI accelerators like NVIDIA and AMD, cloud infrastructure providers scaling AI workloads, networking specialists building high-bandwidth interconnects for data centers, and AI-native software platforms enabling machine learning operations. From chips to cloud to the applications reshaping every industry, these companies form the foundation layer that makes AI possible. The index focuses on US-listed companies deriving over 30% of revenue or strategic growth from AI infrastructure, excluding pure consumer AI applications and generic enterprise software with basic AI features.

US
ACCE Biotech Catalysts

Binary catalyst pipeline — FDA approvals, late-stage trial readouts, and M&A targets. High conviction names with visible catalysts.

Performance windows
PeriodACCE AI InfrastructureACCE Biotech CatalystsSpread
1M+31.4%-1.3%+32.6%
3M+11.4%-11.5%+22.9%
YTD+11.4%-7.6%+19.0%
1Y+11.4%-7.6%+19.0%
3Y+11.4%-7.6%+19.0%
5Y+11.4%-7.6%+19.0%
Inception+11.4%-7.6%+19.0%
ACCE AI Infrastructure — risk
Volatility 30d+30.6%
Volatility 90d+26.6%
Sharpe 90d1.30
Max drawdown-16.5%
Beta vs AIQ1.57
ACCE Biotech Catalysts — risk
Volatility 30d+21.6%
Volatility 90d+25.2%
Sharpe 90d-1.05
Max drawdown-13.4%
Beta vs SPY0.91
Constituent overlap
0 stocks held by both indices (out of 11 and 6)
Top sectors — ACCE AI Infrastructure
Technology70.2%
Communication Services27.6%
Consumer Cyclical2.2%
Top sectors — ACCE Biotech Catalysts
Healthcare100.0%
ACCE Verdict
ACCE AI Infrastructure has crushed ACCE Biotech Catalysts since inception, delivering 11.39% returns versus biotech's -7.6% loss—a nearly 19 percentage point advantage that reflects AI's structural tailwinds versus biotech's binary risk profile. Both indices carry similar volatility around 25-26%, but AI Infrastructure's 1.30 Sharpe ratio demolishes biotech's -1.05 reading, while biotech's slightly lower maximum drawdown of -13.4% versus -16.5% offers cold comfort given the negative returns. These indices share virtually nothing beyond high volatility—AI Infrastructure rides the compute revolution with established revenue streams from NVIDIA-type plays, while Biotech Catalysts bets on FDA lottery tickets and trial outcomes with no revenue visibility. AI Infrastructure suits growth investors seeking exposure to the defining technology trend of the decade, backed by real revenue growth and expanding margins. Biotech Catalysts appeals to speculative traders comfortable with binary outcomes and willing to stomach negative expected returns for the possibility of 10x winners on drug approvals. The data makes this choice straightforward: AI Infrastructure offers superior risk-adjusted returns in a sector with structural demand, while biotech delivers the volatility without the upside.